HN 2301
Alternative Names: HN-2301Latest Information Update: 09 Apr 2025
At a glance
- Originator Shenzhen MagicRNA Biotechnology
- Class CAR-T cell therapies; Lipids; RNA
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Systemic lupus erythematosus
- Research Myasthenia gravis
Most Recent Events
- 25 Mar 2025 Clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (Parenteral) (NCT06801119)
- 30 Jan 2025 Shenzhen MagicRNA Biotechnology plans a clinical trial for Systemic lupus erythematosus (Treatment experienced) in China (Parenteral) (NCT06801119)
- 30 Jan 2025 Early research in Myasthenia gravis in China (Parenteral) (Shenzhen MagicRNA Biotechnology Pipeline, February 2025)